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Abstract
Pancreatic cancer is a disease with a poor prognosis. Most patients are diagnosed at an advanced and unresectable
stage. Even if the primary cancer is radically removed, postoperative recurrence frequently occurs. Generally, metastatic
liver tumors from pancreatic cancer are not indicated for surgical treatment. Here we evaluate the results of performing
hepatectomy for liver metastases of pancreatic cancer. In our institute, six patients with liver metastases from pancreatic
cancer were treated by partial hepatectomy. Overall 1-, 3- and 5-year survival rates of six patients after hepatectomy
were 66.7%, 33.3% and 16.7%, respectively, and one patient was alive for 65.4 months. Performing a hepatectomy for
liver metastases of pancreatic cancer, when combined with a pancreas resection, was recently considered to be a
safe operation, and one that might offer prolonged survival for highly selected patients with curative resection of
liver metastases. In the future, it will be necessary to develop new multi-modality therapies to improve the prognosis
of pancreatic cancer.
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Introduction
Pancreatic cancer has one of the worst prognoses of all
gastrointestinal malignancies. When this cancer is
detected using several examinations, many cases are
already in well-advanced stages of metastases and
dissemination with peripheral invasion of the
retroperitoneum, vascular system, or nerves. The
rate of resection is B/10% and the 5-year survival
rate is 7/25% in the curative resected cases [1/6].
Frequently, the types of recurrences from pancreatic
cancer are liver metastases and peritoneum
dissemination. These recurrent diseases are usually
treated with palliative operations, chemotherapy or
radiotherapy, rather than radical operations. Hepa-
tectomy is a safe and potentially curative treatment for
liver metastases from colorectal cancer and some
kinds of malignancies [7,8]. There are some reports
discussing hepatectomy for liver metastases from
pancreatic cancer [9/25]. Here we review our
experience with hepatectomy for treating metastatic
nonneuroendocrine pancreatic cancer.
Patients and methods
From 1991 to 1995, 33 patients underwent hepatect-
omy for metastases from noncolorectal and nonneuro-
endocrine tumors in Hokkaido University Hospital
and affiliated hospitals. Six patients (18.2%) under-
went curative hepatectomy for liver metastases from
pancreatic cancer. Prerequisites for a hepatectomy
were: (1) the feasibility of a complete excision of all
intrahepatic disease, (2) reliable control of the
primary disease by means of extirpation, and (3) no
extrahepatic diseases at the time of detection of
resectable liver metastases. When liver metastases
were combined with extrahepatic recurrences, hepatic
resection was not indicated and systemic chemother-
apy or radiotherapy was used to treat these recurrent
diseases.
Results
The patients included one female and five males
ranging between 48 and 77 years of age (average
ISSN 1365-182X print/ISSN 1477-2574 online # 2006 Taylor & Francis
DOI: 10.1080/13651820500472200
Correspondence: Hidehisa Yamada, MD, PhD, Department of Surgical Oncology, Division of Cancer Medicine, Hokkaido University Graduate School of
Medicine, North 15, West 7, Kita-ku, Sapporo, 060-8648, Japan. Tel: /81 11 716 1161(5932). Fax: /81 11 706 7158. E-mail: hy0823@hotmail.co.jp
HPB, 2006; 8: 85/88
60.8). The histopathological types of primary
pancreatic cancer were ductal adenocarcinoma in
four patients, adenosquamous carcinoma in one,
and cystadenocarcinoma in one. None were neuroen-
docrine cell tumors. Lymph node status of origin was
positive in three patients and negative in three. The
timing of liver metastases was almost synchronous in
five and metachronous in one. The diameter of liver
tumors ranged from 1 to 7 cm (average 2.6 cm). Small
nodules B/2 cm were shown in four patients. The
operative method of hepatectomy was partial
resection for all patients. Curative hepatectomy with
no microscopic residual tumor on the edge of the liver
was performed in five patients, but only one case was
a macroscopic non-curative operation. There were no
operative mortalities, but there were two complica-
tions (bleeding of duodenal ulcer and leakage from
pancreatojejunal anastomosis). Recurrence after he-
patectomy occurred in four patients, thereby
excluding one noncurative patient. The recurrent
lesions included remnant liver, peritoneum, and
bone. One patient has survived with no evidence of
recurrence for 5 years. Five patients died of cancer
recurrence from 4.6 to 52 months after their hepa-
tectomy. Overall 1-, 3- and 5-year survival rates of six
patients after hepatectomy were 66.7%, 33.3%, and
16.7%, respectively (Figure 1).
Discussion
Since hepatectomy for liver metastases from pancrea-
tic cancer were first reported in 1982, some groups
performed hepatectomy aggressively [8/25] (Table I).
Previous studies showed that morbidity ranged from
19% to 35% and mortality from 0% to 20% for
hepatectomy [14,18,19,21,23]. In our study, the two
cases with complications did not need further
operative treatment, and the mortality rate was 0%.
As a result of recent advances in surgery, synchronous
resection of the pancreas and liver has been made safe.
Then, these results showed that the survival time
after hepatectomy was B/1 year. There were just two
long-term survivors noted in past literature [8,18].
One case was alive with no evidence of relapse for
65.4 months and the other case, with a cystadeno-
carcinoma of the pancreas, was alive for 70 months
after a hepatectomy. In our report, one patient with
the same type of cancer survived for 52.0 months after
a hepatectomy. The biological behavior of this
type may be different from pancreatic ductal
adenocarcinoma.
Prognostic factors of noncolorectal and nonneur-
oendocrine liver metastases were reported to be the
site of primary tumor, disease-free interval between
resection of primary tumor and hepatectomy, and
curative surgical margin. Most liver metastases from
pancreatic cancer tend to be detected synchronously,
Figure 1. Overall survival curves after hepatectomy of liver metas-
tases from pancreatic cancer.
Table I. Published reports on hepatectomy of liver metastases from pancreatic cancer.
Ref. no. Year Authors Number of patients Prognosis
9 1982 Morrow et al. 1 /
10 1983 Thompson et al. 2 /
11 1986 Ekberg et al. 1 /
12 1987 Sesto et al. 1 /
13 1995 Schildberg et al. 5 3 years 0%, median 7 months
14 1997 Harrison et al. 2 /
15 1997 Howard 10 5/30 months (median 11)
16 1997 Takada et al. 11 Mean 6 months
17 1998 Lindell et al. 2 0.8 and 5 months
18 1998 Berney et al. 2 1 long-term survivor (70 months)
19 1998 Elias et al. 1 /
20 2000 Hemming et al. 2 /
21 2000 Benevento et al. 1 /
22 2001 Laurent et al. 2 /
23 2001 Takada et al. 2 7 and 22 months
8 2001 Yamada et al. 6 3 years 33%, 5 years 16%
24 2003 Pawlik et al. 4 /
25 2005 Weitz et al. 5 /
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yielding a poor prognostic factor. However, it is not
clear which characteristic factors are associated with
good survival prognoses. In our experience, there
was one 5-year survivor and three patients who
survived for over 2 years. Most tumors were single
and small in size. We believe that the resection of liver
metastases from pancreatic cancer might be an
effective treatment for highly selected patients, and
further study is needed to clarify the role of
hepatectomy because of the small number of patients
in our series.
Thus, surgical treatment alone for liver metastases
from pancreatic cancer cannot offer long-term
survival for many patients with this disease. Yet, other
treatments such as chemotherapy and radiotherapy
also do not show positive outcome data. Studies of
5-fluorouracil (5-FU)-based postoperative chemora-
diotherapy were reported by some groups [26/28],
but their results failed to show that postoperative
chemoradiotherapy had positive survival benefits
for patients with pancreatic cancer. Since 1997
gemcitabine has been used as a systemic chemo-
therapy combined with radiotherapy. Many trials,
using other anti-cancer drugs such as taxan, or
new regimens such as preoperative chemoradiother-
apy, have been performed. When standard strategies
for pancreatic cancer with or without liver metastases
are established, surgical treatment combining
these chemotherapies with, perhaps, radiotherapy,
may lead to improved prognoses for pancreatic
cancer.
In conclusion, performing hepatectomy for metas-
tases from pancreatic cancer might offer prolonged
survival for highly selected patients with curative
resection of liver metastases, and we should develop
new multi-modality therapies for advanced pancreatic
cancer in the future.
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